While previous studies have predominantly identified BCL6 as a hematopoietic tumor-specific oncogene (Kawabata et al., 2021), intriguing emerging data have also linked BCL6 to the regulation of the progression of solid tumors, such as lung cancer (Li et al., 2022), breast cancer (Yu et al., 2015), and ovarian cancer. The gene discussed is BCL6; the disease is lung carcinoma.